Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of NEVRO CORP from 31 Dec 2016 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
NEVRO CORP quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 31 Dec 2016 to 31 Dec 2024.
  • NEVRO CORP Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 31 Dec 2024 was $95,051,000, a 9.3% decline year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

NEVRO CORP Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $95,051,000 -$9,772,000 -9.3% 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q4 2023 $104,823,000 -$16,156,000 -13% 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q4 2022 $120,979,000 31 Dec 2022 10-K 04 Mar 2025 2024 FY
Q2 2018 $41,644,000 +$15,969,000 +62% 30 Jun 2018 10-Q 02 Aug 2018 2018 Q2
Q1 2018 $28,456,000 +$8,454,000 +42% 31 Mar 2018 10-Q 07 May 2018 2018 Q1
Q4 2017 $43,651,000 +$1,439,000 +3.4% 31 Dec 2017 10-Q 02 Aug 2018 2018 Q2
Q2 2017 $25,675,000 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $20,002,000 31 Mar 2017 10-Q 07 May 2018 2018 Q1
Q4 2016 $42,212,000 31 Dec 2016 10-Q 02 Aug 2018 2018 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.